Gene therapy in the inner ear: Mechanisms and clinical implications

Thomas R Van De Water, Hinrich Staecker, Marc W. Halterman, Howard J. Federoff

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The application of gene therapy to the inner ear is an emerging field of study. Most studies report the expression of marker genes (e.g., galactosidase) within the tissues of the cochlea. The first biologic response of an inner ear tissue (i.e., auditory neurons) to transduction by a gene therapy vector expressing a therapeutic gene (a herpes amplicon vector containing a BDNF gene) was observed in spiral explants obtained from early postnatal rat cochleae. This study was important because it demonstrated the feasibility of a gene augmentation approach to treat traumatized cochleae. Long-term expression of transduced or transfected genes in cochlear tissues have been obtained with adenovirus, adeno-associated virus, and herpes amplicon vectors. The herpes amplicon vector (i.e., HSVbdnflac) that evoked a biologic response in vitro has also been successfully used to support the survival of auditory neurons in vivo following loss of the auditory hair cells (i.e., loss of trophic factor). Gene therapy has been successfully applied to the cochlea of a laboratory animal, and future studies will define the types of vectors and therapeutic genes that will work best for the treatment of inner ear diseases in the clinic.

Original languageEnglish
Pages (from-to)345-360
Number of pages16
JournalAnnals of the New York Academy of Sciences
Volume884
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Gene therapy
Cochlea
Inner Ear
Genetic Therapy
Genes
Tissue
Auditory Hair Cells
Labyrinth Diseases
Neurons
Galactosidases
Dependovirus
Brain-Derived Neurotrophic Factor
Laboratory Animals
Adenoviridae
Viruses
Therapeutics
Ear
Gene
Gene Therapy
Rats

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Van De Water, T. R., Staecker, H., Halterman, M. W., & Federoff, H. J. (1999). Gene therapy in the inner ear: Mechanisms and clinical implications. Annals of the New York Academy of Sciences, 884, 345-360.

Gene therapy in the inner ear : Mechanisms and clinical implications. / Van De Water, Thomas R; Staecker, Hinrich; Halterman, Marc W.; Federoff, Howard J.

In: Annals of the New York Academy of Sciences, Vol. 884, 01.01.1999, p. 345-360.

Research output: Contribution to journalArticle

Van De Water, TR, Staecker, H, Halterman, MW & Federoff, HJ 1999, 'Gene therapy in the inner ear: Mechanisms and clinical implications', Annals of the New York Academy of Sciences, vol. 884, pp. 345-360.
Van De Water TR, Staecker H, Halterman MW, Federoff HJ. Gene therapy in the inner ear: Mechanisms and clinical implications. Annals of the New York Academy of Sciences. 1999 Jan 1;884:345-360.
Van De Water, Thomas R ; Staecker, Hinrich ; Halterman, Marc W. ; Federoff, Howard J. / Gene therapy in the inner ear : Mechanisms and clinical implications. In: Annals of the New York Academy of Sciences. 1999 ; Vol. 884. pp. 345-360.
@article{1c957933e3094d2da47ee65b6908be39,
title = "Gene therapy in the inner ear: Mechanisms and clinical implications",
abstract = "The application of gene therapy to the inner ear is an emerging field of study. Most studies report the expression of marker genes (e.g., galactosidase) within the tissues of the cochlea. The first biologic response of an inner ear tissue (i.e., auditory neurons) to transduction by a gene therapy vector expressing a therapeutic gene (a herpes amplicon vector containing a BDNF gene) was observed in spiral explants obtained from early postnatal rat cochleae. This study was important because it demonstrated the feasibility of a gene augmentation approach to treat traumatized cochleae. Long-term expression of transduced or transfected genes in cochlear tissues have been obtained with adenovirus, adeno-associated virus, and herpes amplicon vectors. The herpes amplicon vector (i.e., HSVbdnflac) that evoked a biologic response in vitro has also been successfully used to support the survival of auditory neurons in vivo following loss of the auditory hair cells (i.e., loss of trophic factor). Gene therapy has been successfully applied to the cochlea of a laboratory animal, and future studies will define the types of vectors and therapeutic genes that will work best for the treatment of inner ear diseases in the clinic.",
author = "{Van De Water}, {Thomas R} and Hinrich Staecker and Halterman, {Marc W.} and Federoff, {Howard J.}",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "884",
pages = "345--360",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Gene therapy in the inner ear

T2 - Mechanisms and clinical implications

AU - Van De Water, Thomas R

AU - Staecker, Hinrich

AU - Halterman, Marc W.

AU - Federoff, Howard J.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The application of gene therapy to the inner ear is an emerging field of study. Most studies report the expression of marker genes (e.g., galactosidase) within the tissues of the cochlea. The first biologic response of an inner ear tissue (i.e., auditory neurons) to transduction by a gene therapy vector expressing a therapeutic gene (a herpes amplicon vector containing a BDNF gene) was observed in spiral explants obtained from early postnatal rat cochleae. This study was important because it demonstrated the feasibility of a gene augmentation approach to treat traumatized cochleae. Long-term expression of transduced or transfected genes in cochlear tissues have been obtained with adenovirus, adeno-associated virus, and herpes amplicon vectors. The herpes amplicon vector (i.e., HSVbdnflac) that evoked a biologic response in vitro has also been successfully used to support the survival of auditory neurons in vivo following loss of the auditory hair cells (i.e., loss of trophic factor). Gene therapy has been successfully applied to the cochlea of a laboratory animal, and future studies will define the types of vectors and therapeutic genes that will work best for the treatment of inner ear diseases in the clinic.

AB - The application of gene therapy to the inner ear is an emerging field of study. Most studies report the expression of marker genes (e.g., galactosidase) within the tissues of the cochlea. The first biologic response of an inner ear tissue (i.e., auditory neurons) to transduction by a gene therapy vector expressing a therapeutic gene (a herpes amplicon vector containing a BDNF gene) was observed in spiral explants obtained from early postnatal rat cochleae. This study was important because it demonstrated the feasibility of a gene augmentation approach to treat traumatized cochleae. Long-term expression of transduced or transfected genes in cochlear tissues have been obtained with adenovirus, adeno-associated virus, and herpes amplicon vectors. The herpes amplicon vector (i.e., HSVbdnflac) that evoked a biologic response in vitro has also been successfully used to support the survival of auditory neurons in vivo following loss of the auditory hair cells (i.e., loss of trophic factor). Gene therapy has been successfully applied to the cochlea of a laboratory animal, and future studies will define the types of vectors and therapeutic genes that will work best for the treatment of inner ear diseases in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=0032787488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032787488&partnerID=8YFLogxK

M3 - Article

C2 - 10842605

AN - SCOPUS:0032787488

VL - 884

SP - 345

EP - 360

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -